You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Anticholinergic activity and cognitive decline in Parkinson's disease
  1. Sergio E Starkstein
  1. Correspondence to Professor S E Starkstein, Fremantle Hospital, Education Building T-7, Fremantle 6959, Australia; ses{at}meddent.uwa.edu.au

https://doi.org/10.1136/jnnp.2009.194548

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Anticholinergic activity of medications may produce significant cognitive decline in Parkinson's disease.

    In this issue, Ehrt et al (see page 160) report that patients with Parkinson's disease (PD) treated with a variety of medications with anticholinergic activity had a significantly greater cognitive decline than patients with PD never medicated with those drugs. This is the first longitudinal study to show a detrimental effect of drugs with anticholinergic activity in PD. The relevance of the findings is increased by the large sample included in the study, the fact that patients were recruited from a community based cohort, by …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; not externally peer reviewed.

    Linked Articles